|Therapy Name||Atezolizumab + KY1044|
KY1044 is a monoclonal antibody that targets ICOS, which has potential anti-tumor activity (Cancer Res 2018;78(13 Suppl):Abstract nr 2792).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Atezolizumab||Tecentriq||RG7446|MPDL3280A||Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 51||Tecentriq (atezolizumab) is a monoclonal antibody against PD-L1 (CD274), preventing activation of its receptor, potentially enhancing T-cell-mediated immune response to neoplasms and inhibiting T-cell inactivation (PMID: 29449897). Tecentriq (atezolizumab) is FDA approved for use in patients with advanced urothelial carcinoma, metastatic non-small cell lung cancer (NSCLC) progressed on platinum-containing therapy, in combination with bevacizumab, paclitaxel, and carboplatin for non-squamous NSCLC with no EGFR or ALK aberrations, in combination with paclitaxel protein-bound for advanced or metastatic triple-negative breast cancer expressing PD-L1, and in combination with carboplatin and etoposide for small cell lung cancer (FDA.gov).|
|KY1044||KY1044 is a monoclonal antibody that targets ICOS, which has potential anti-tumor activity (Cancer Res 2018;78(13 Suppl):Abstract nr 2792).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03829501||Phase Ib/II||Atezolizumab + KY1044 KY1044||Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer||Recruiting|